These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31866768)

  • 1. Differential discounting in the economic evaluation of healthcare programs.
    John J; Koerber F; Schad M
    Cost Eff Resour Alloc; 2019; 17():29. PubMed ID: 31866768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis.
    Schad M; John J
    Eur J Health Econ; 2012 Apr; 13(2):127-44. PubMed ID: 21170731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating implied rates of discount in healthcare decision-making.
    West RR; McNabb R; Thompson AG; Sheldon TA; Grimley Evans J
    Health Technol Assess; 2003; 7(38):1-60. PubMed ID: 14622489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discounting and decision making in the economic evaluation of health-care technologies.
    Claxton K; Paulden M; Gravelle H; Brouwer W; Culyer AJ
    Health Econ; 2011 Jan; 20(1):2-15. PubMed ID: 21154521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discounting health effects in pharmacoeconomic evaluations: current controversies.
    Bos JM; Postma MJ; Annemans L
    Pharmacoeconomics; 2005; 23(7):639-49. PubMed ID: 16173156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discounting in the economic evaluation of health care interventions.
    Krahn M; Gafni A
    Med Care; 1993 May; 31(5):403-18. PubMed ID: 8501989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The practice of discounting in economic evaluations of healthcare interventions.
    Smith DH; Gravelle H
    Int J Technol Assess Health Care; 2001; 17(2):236-43. PubMed ID: 11446135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On discounting of health gains from human papillomavirus vaccination: effects of different approaches.
    Westra TA; Parouty M; Brouwer WB; Beutels PH; Rogoza RM; Rozenbaum MH; Daemen T; Wilschut JC; Boersma C; Postma MJ
    Value Health; 2012 May; 15(3):562-7. PubMed ID: 22583467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On discount rates for economic evaluations in global health.
    Haacker M; Hallett TB; Atun R
    Health Policy Plan; 2020 Feb; 35(1):107-114. PubMed ID: 31625564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discounting in cost-utility analysis of healthcare interventions: reassessing current practice.
    Cohen BJ
    Pharmacoeconomics; 2003; 21(2):75-87. PubMed ID: 12515570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discounting in economic evaluation of healthcare interventions: what about the risk term?
    Hultkrantz L
    Eur J Health Econ; 2021 Apr; 22(3):357-363. PubMed ID: 33616779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review.
    Jit M; Mibei W
    Vaccine; 2015 Jul; 33(32):3788-94. PubMed ID: 26144897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discounting compensation for injuries.
    Price C
    Risk Anal; 2000 Dec; 20(6):839-49. PubMed ID: 11314733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discounting in decision making: the consistency argument revisited empirically.
    Brouwer WB; van Exel NJ
    Health Policy; 2004 Feb; 67(2):187-94. PubMed ID: 14720636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discounting in Economic Evaluations.
    Attema AE; Brouwer WBF; Claxton K
    Pharmacoeconomics; 2018 Jul; 36(7):745-758. PubMed ID: 29779120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discounting for health effects in cost-benefit and cost-effectiveness analysis.
    Gravelle H; Smith D
    Health Econ; 2001 Oct; 10(7):587-99. PubMed ID: 11747043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theoretical arguments for the discounting of health consequences: where do we go from here?
    Lazaro A
    Pharmacoeconomics; 2002; 20(14):943-61. PubMed ID: 12403636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries.
    Lomas J; Claxton K; Ochalek J
    Health Policy Plan; 2022 Jan; 37(1):45-54. PubMed ID: 34410385
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.